BioCentury
ARTICLE | Clinical News

Malaria vaccine shows promise in Phase Ia trial

January 5, 2017 12:09 AM UTC

In a study published Wednesday in Science Translational Medicine, researchers at the Center for Infectious Disease Research and Fred Hutchinson Cancer Research Center said a vaccine using genetically attenuated parasites prevented malaria infection in all 10 volunteers in a human challenge model.

The team created the GAP3KO vaccine by knocking out three genes in Plasmodium falciparum - p52, p36 and sap1 - expressed in the pre-erthryocytic stage that are necessary for liver-stage development. In mice, immunization with GAP3KO provided complete protection against malaria infection. ...